"Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings" - Krithika Subramanian
The addition of novel agents and combinations to the treatment of multiple myeloma, along with improvements in personalized therapy based on genetic profiles of individual patients, are propelling care forward with their potential for prolonging survival and deepening responses beyond those from the current standards of care. “STORM Part 2 represents the largest, most heavily pretreated population with MM in a prospective clinical trial to date,” said Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital. He added, “Patients received a median of seven prior therapies over 6.6 years. These patients have no known available therapies with clinical benefit.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press ReleasesScientists Create Most Powerful, Accurate Tool Yet to Research Deadliest Blood Cancer
Apr 18, 2023 View All Press ReleasesStudy Identifies New Gene That Drives Colon Cancer
Oct 14, 2022 View All Press ReleasesMount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
Jun 16, 2022 View All Press Releases